Hepcidin: A Critical Regulator of Iron Metabolism during Hypoxia by Hintze, Korry J. & McClung, James P.
Hindawi Publishing Corporation
Advances in Hematology
Volume 2011, Article ID 510304, 7 pages
doi:10.1155/2011/510304
Review Article
Hepcidin:A CriticalRegulator of
Iron Metabolism during Hypoxia
Korry J. Hintze1 andJames P.McClung2
1Department of Nutrition, Dietetics & Food Sciences, Utah State University, Logan, UT 84322, USA
2Military Nutrition Division, US Army Research Institute of Environmental Medicine (USARIEM), Natick, MA 01760, USA
Correspondence should be addressed to James P. McClung, james.mcclung@amedd.army.mil
Received 27 May 2011; Accepted 8 July 2011
Academic Editor: Angela Panoskaltsis-Mortari
Copyright © 2011 K. J. Hintze and J. P. McClung. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Iron status aﬀects cognitive and physical performance in humans. Recent evidence indicates that iron balance is a tightly regulated
process aﬀected by a series of factors other than diet, to include hypoxia. Hypoxia has profound eﬀects on iron absorption and
results in increased iron acquisition and erythropoiesis when humans move from sea level to altitude. The eﬀects of hypoxia on
iron balance have been attributed to hepcidin, a central regulator of iron homeostasis. This paper will focus on the molecular
mechanisms by which hypoxia aﬀects hepcidin expression, to include a review of the hypoxia inducible factor (HIF)/hypoxia
response element (HRE) system, as well as recent evidence indicating that localized adipose hypoxia due to obesity may aﬀect
hepcidin signaling and organismal iron metabolism.
1. Iron: An Essential Trace Element
Despite the initial identiﬁcation of iron as a major com-
ponent of human blood over two hundred years ago, poor
iron status continues to aﬀect billions of people worldwide.
Although the prevalence of iron deﬁciency (diminished iron
stores, ID) and iron deﬁciency anemia (diminished iron
stores coupled with reduced hemoglobin, IDA) is greatest
in the developing world, poor iron status also aﬀects a
signiﬁcant portion of the population in developed nations.
For example, ID and IDA aﬀect up to 12 and 4% of
premenopausal women in the United States, respectively
[1]. Iron functions biochemically through incorporation
into a series of proteins and enzymes. Many of these
proteins and enzymes, including myoglobin, cytochrome c,
and hemoglobin, are required for optimal cognitive and
physical performance in humans [2–4]. Although dimin-
ished work capacity due to reduced hemoglobin levels is
the best described functional consequence of poor iron
status, other outcomes include diminished intellectual per-
formance, altered body temperature regulation, and reduced
immunity and resistance to infections [5].
Iron balance has been historically deﬁned as the net
diﬀerence between the amount of iron that is absorbed
from the diet and the amount of iron that is excreted. As
such, countless investigations have focused on dietary factors
aﬀecting iron balance, such as the quantity of iron found
in particular food sources and factors that may promote
or inhibit iron absorption. Although iron consumption
through the diet is clearly a major determinant of iron
status, it has become increasingly apparent that many factors
aﬀect iron balance (Figure 1). In fact, iron balance is tightly
regulated through a series of cellular transport proteins
that are sensitive to the recently discovered iron regulatory
hormone, hepcidin. The discovery of hepcidin, a 25-amino
acid protein, has signiﬁcantly altered the research paradigm
in the ﬁeld of iron homeostasis. Although the contribution
of dietary sources to iron balance should not be ignored,
hepcidin has been described as the “central regulator of iron
homoeostasis,” and aﬀects both iron absorption through the
duodenal enterocyte and iron export from the macrophage
and other iron exporting cells. Further, a series of factors,
some of which are not directly associated with dietary iron
intake, aﬀect hepcidin levels, such as inﬂammation, erythro-
poiesis, and hypoxia. This paper will detail the mechanism
by which hepcidin aﬀects iron metabolism, with a focus
on hypoxia, a factor aﬀecting the molecular regulation of
hepcidin, and, ultimately, iron status.2 Advances in Hematology
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Figure 1: Factors aﬀecting iron balance.
2. Hepcidin: The Central Regulator of
IronHomeostasis
Hepcidin was ﬁrst identiﬁed as an antimicrobial peptide
synthesized by the liver in 2000 [6, 7]. Although hepcidin
confers antimicrobial properties in vitro, the estimated
concentrations found in biological ﬂuids may not support
a major role for this peptide hormone as an antimicrobial
agent in vivo [8]. In 2001, the observation that hepcidin was
overexpressed in response to dietary iron overload led to the
hypothesis that hepcidin may function as a central regulator
of iron homeostasis [9]. Subsequently, roles for hepcidin
in both the acquisition of iron from the gastrointestinal
tract and the eﬄux of iron from macrophages have been
characterized.
Hepcidin regulates iron homeostasis mainly through its
ability to bind ferroportin 1 (FPN1), the iron exporter
responsible for iron egress from duodenal enterocytes,
macrophages, and other iron exporting cells. Speciﬁcally,
hepcidin binds to FPN1 on the cell surface, triggering the
internalization of the hepcidin-FPN1 complex, which results
in the subsequent ubiquitination of the FPN1 and the
degradation of the protein complex [10, 11]. Experimental
evidence conﬁrms this mechanism of hepcidin action:
disruption of the hepcidin gene leads to persistent FPN1
expression on the cell membrane and subsequent iron
overload [12, 13], and delivery of synthetic hepcidin results
in decreased serum iron in response to diminished intestinal
iron absorption [14]. In sum, hepcidin dictates iron balance
by restricting iron absorption and macrophage iron release,
thereby reducing iron stores and aﬀecting the availability of
iron for conferring critical biological functions, including
erythropoiesis [11].
Adding to the complexity of the maintenance of iron
homeostasis, hepcidin synthesis is regulated by a number of
factors, including iron status, inﬂammation, and erythro-
poiesis. The regulation of hepcidin by iron status appears
to occur through the bone morphogenic protein (BMP)
pathway. A number of BMPs, including BMP6, have been
demonstrated to aﬀect hepcidin production, in vivo [15–17].
For example, knockout of BMP6 in a mouse model results in
severeironoverload[16,18],andBMP6expressionincreases
with iron loading in mice [19]. The regulation of hepcidin
synthesis in response to inﬂammation occurs in response
to proinﬂammatory cytokines, including interleukin-6 (IL-
6). Increased circulating concentrations of IL-6, which may
occur in response to inﬂammatory condition such as sepsis,
inﬂammatory bowel disease, and obesity, stimulate hep-
cidin transcription through a STAT3-dependent mechanism
[20–24]. Associations between iron status, inﬂammatory
biomarkers, and hepcidin levels have been documented
in recent human trials [25]. Erythropoiesis, the biologic
process requiring the greatest concentrations of body iron,
is a suppressor of hepcidin production [24]. Both human
and animal studies have demonstrated reductions in serum
hepcidin and mRNA levels, respectively, following erythro-
poietin administration [26, 27]. Although the ﬁnite mech-
anism by which erythropoiesis aﬀects hepcidin production
remains unknown, early evidence indicates that two proteins
produced by erythroid precursors are involved in hepcidin
regulation. Growth diﬀerentiation factor 15 (GDF15) has
been demonstrated to suppress hepcidin expression and
is elevated in patients with thalassemia [28]. Another
erythrokine, twisted gastrulation protein (TWSG1), has also
been shown to suppress hepcidin mRNA in vitro [29].
Hypoxia is another factor that may aﬀect hepcidin regu-
lation, potentially through increased erythropoietin (EPO)
production. The remainder of this paper will focus on
potential mechanisms by which hypoxia may aﬀect hepcidin
levels, and, subsequently, iron homeostasis.
3. Hypoxiaand IronMetabolism
The profound eﬀects of hypoxia on organismal iron
metabolism have been well described. Early studies demon-
strated that hypoxia aﬀected dietary iron absorption [30–
32] and increased erythropoiesis when humans were moved
from sea level to high altitude [33]. As the partial pressure
of O2 decreases through increased elevation, anemia, or
localized tissue hypoxia, a battery of genes are induced by
thehypoxiainduciblefactor(HIF)/hypoxiaresponseelement
(HRE) system. The HIF system senses O2 levels through
degradation of HIF transcription factors (HIF-1α and HIF-
2α) that are mediated by the partial pressure of O2 and iron-
dependent hydroxylases. At normoxic O2 tensions, HIF-1α
is hydroxylated by prolyl hydroxylase and then bound by
the von Hippel-Lindau (VHL) protein leading ultimately to
ubiquitinationandproteasomedegradation.Duringhypoxic
conditions, the activity of hydroxylases is inhibited allowing
HIF-1α to accumulate and bind along with HIF-1β to HRE
found in the promoters of target genes. Similar to HIF-1α,
HIF-2α stability is mediated by the partial pressure of O2
through prolyl hydroxylase and plays a dominant role in
hypoxic signaling of EPO expression [34].
4. Hypoxiaand HepcidinExpression
Reduced expression of hepcidin during hypoxia was ﬁrst
reported in 2002 by Nicolas et al. [35], who demonstrated
a marked reduction in hepcidin mRNA in HepG2 cells
cultured at 2 and 0.1% O2 compared to standard 20%
O2 culture conditions. Similarly, when mice were placed
in atmospheric chambers emulating an altitude of 5,500m,
hepcidin expression was downregulated after 48hrs ofAdvances in Hematology 3
hypoxia. Leung et al. [36] also reported decreased hepcidin
mRNA expression in HepG2 cells cultured at 1% O2
and in liver from rats placed in atmospheric chambers
containing 10% O2. However, the molecular mechanisms
linking hypoxia and decreased hepcidin expression remained
unexplained. Because the HIF signaling system imparts a
dominant role in sensing O2 deprivation and subsequent
geneexpression,including theupregulationofEPO[37],itis
aprobable,directorupstream,mediatorofhypoxia-induced,
hepcidin gene regulation.
Peyssonnaux and colleagues [38] demonstrated that the
expected hepcidin downregulation in response to dietary
iron deﬁciency was partially blunted in hepatocyte-speciﬁc
HIF-1α knockout mice as compared to wild-type animals,
suggesting that HIF-1α might be a negative regulator
of hepcidin signaling. Moreover, hepatocyte-speciﬁc VHL
knockout mice have higher HIF-1 levels but reduced hep-
cidin expression and increased hepatic ferroportin levels,
further suggesting a role for the HIF system as a negative
hepcidin regulator. Peyssonnaux et al. [38]w e n to nt o
demonstrate that murine and human hepcidin promoters
contained a consensus HRE that could be immunoprecip-
itated by a HIF-1α antibody when cells were treated with
the iron chelator and HIF-1α stabilizer desferrioxamine
(DFO). Taken together, these data provided evidence that
the HIF system is a negative regulator of hepcidin expression
and provided a mechanism whereby hypoxia may decrease
hepcidin expression. Typically, the HIF system functions
as a positive regulator of gene expression [37]; however,
negative transcriptional regulation by the HIF system is not
unprecedented [39].
Studies by Braliou et al. [40] tested whether 2-
oxoglutarate-dependent oxygenases mediated hepcidin reg-
ulation in response to hypoxia. Similar to studies by Nicolas
et al. [35] and Leung et al. [36], hypoxia decreased hepcidin
expression in both HepG2 and Huh7 cells. Hepcidin expres-
sion was also decreased by hypoxia mimetics, including
dimethyloxaloylglycine (DMOG), DFO, and CoCl2. These
mimetics function by stabilizing the HIF pathway by inhibit-
ing 2-oxoglutarate-dependent oxygenases and thus prevent-
ing HIF-1α hydroxylation and destruction. While hypoxia,
DFO, and CoCl2 only modestly decreased hepcidin expres-
sion, DMOG dramatically decreased hepcidin expression in
both cell lines. Despite negative regulation by hypoxia and
hypoxia mimetics, overexpression or knockdown of HIF-1α
had no eﬀect on hepcidin promoter activity suggesting
that HIF-1α is not directly involved in hepcidin promoter
transcriptional regulation. In a similar study by Choi et al.
[41], hypoxia decreased hepcidin expression in both mice
and HepG2 cells, and the cell culture studies indicated that
decreased hepcidin expression was independent of HIF-1α.
The authors concluded that hypoxia-induced oxidative stress
decreased STAT3 and C/EBPα protein/DNA interactions,
thus resulting in decreased hepcidin expression.
Interestingly, not all studies have demonstrated that
hypoxia directly decreases in vitro hepcidin expression. In
an investigation by Volke et al. [42], HepG2 and Huh7
cells cultured under hypoxic conditions did not have dimin-
ished hepcidin expression, contrary to previous reports
[35, 36, 40]. However, similar to the study by Braliou
et al. [40], the hypoxia mimetic DMOG, as well as the
iron chelator 2,2dipyridyl, decreased hepcidin expression.
Moreover, Volke et al. [42] demonstrated that HIF-1α or
HIF-1β knockdown did not increase hepcidin expression
and concluded that reductions in hepcidin expression from
hypoxia mimetics were not mediated through HIF. Also
contrary to previous reports [35, 36, 38, 40, 41], Chaston
et al. [43] reported that hypoxia increased Huh7 hepcidin
expression. However, when Huh7 cells were cocultured with
activated THP-1 macrophages, hypoxia reduced hepcidin
expression. Using reporter constructs under control of the
hepcidin promoter and the THP-1 coculture model, the
investigators demonstrated that hypoxia-induced hepcidin
repression in Huh7 cells was abrogated when the SMAD
binding site was mutated. Mutations to the Ebox1,2, STAT3,
a n dC / E B Ps i t e sh a dn oe ﬀect, suggesting that hypoxia-
mediated hepcidin regulation is controlled through the
SMAD site and is dependent on macrophage coculture.
SMAD regulation of the hepcidin promoter is mediated
through BMPs and bone morphogenetic response elements
(BRE) in the hepcidin promoter. Binding of BMPs to their
receptorscausesphosphorylationofSMADproteins,binding
to the BRE and increased gene expression. The gene product
of the HFE2 gene, hemojuvelin, is a coreceptor for BMP
proteins, and overexpression increases hepcidin expression
in liver cells [17]. Regulation of hepcidin through BMP
is independent of inﬂammatory signaling through STAT3,
thus hepcidin may be regulated independently by diﬀerent
stimuli. It has been hypothesized that regulation of hepcidin
by hemojuvelin is dependent upon whether hemojuvelin
is membrane anchored or soluble. Membrane-anchored
hemojuvelin is a positive regulator of the BMP/SMAD
cascade, whereas soluble hemojuvelin functions as a dummy
receptor, inhibits the pathway, and results in reduced hep-
cidin expression [44].
Severalstudieshaveprovidedevidencethathepcidinmay
be regulated by hypoxia through the hemojuvelin/BMP axis
and hypoxic regulation of the hemojuvelin cleaving proteins
matripase-2 (TMPRSS6) and furin. Du et al. [45]ﬁ r s t
reported that mice with a homozygous TMPRSS6 mutation,
referred to as mask, have compromised iron status due to
excessive hepcidin signaling. Moreover, hepcidin promoter
activation by cotransfection of a hemojuvelin expression
construct or recombinant BMP2, BMP4, or BMP9 proteins
was blunted when cells were treated with a wild-type
TMPRSS6 expression vector but not with a vector coding
for TMPRSS6 with the mask mutation. Folgueras et al. [46]
and Finberg et al. [47] further demonstrated the importance
of TMPRSS6 on hepcidin regulation by demonstrating that
TMPRSS6 knockout mice have elevated hepcidin levels
and decreased iron stores compared to wild-type mice.
Furthermore, TMPRSS6 mutations have been described in
humans and result in aberrant hepcidin signaling and iron-
refractory iron-deﬁciency anemia [48–51]. TMPRSS6 was
demonstrated by Silvestri et al. [52] to cleave membrane
hemojuvelin and inhibit hepcidin expression. The same
research group [53] also reported that hemojuvelin can
be cleaved by furin in the endoplasmic reticulum. Furin4 Advances in Hematology
promoter activity was increased by the HIF stabilizers DFO
and CoCl2 and decreased by ferric ammonium citrate
treatment suggesting HIF regulation. This is supported by an
earlierstudydemonstratingthatfurinexpressionispositively
regulated by hypoxia via the HIF pathway [54].
Recently, Lakhal et al. [55] demonstrated that TMPRSS6
is regulated by hypoxia through HIF-1α and 2α. TMPRSS6
gene expression increased in Hep3B cells when cultured
at 0.5% O2 and in the presence of the hypoxia mimetic
DMOG. Increased TMPRSS6 expression induced by hypoxia
or hypoxia mimetics was curtailed by siRNA knockdown of
HIF-1α and/or 2α. It was also reported that hypoxia reduced
membranehemojuvelinandthiseﬀectcouldbeabrogatedby
siRNA knockdown of TMPRSS6, HIF-1α,a n d2 α.H y p o x i a
decreased activity of luciferase constructs containing the
proximal hepcidin BRE, and this eﬀect was inhibited when
cells were treated with either TMPRSS6 or HIF-1α and 2α
siRNA or if the promoter BRE was mutated.
5.LocalizedAdipose Hypoxiaand
HepcidinExpression
Early studies have demonstrated a link between obesity
and poor iron status [56, 57] .S t u d i e sh a v ed e m o n s t r a t e d
this association in children and adolescents [57–60], adult
men and women [61–64], and postmenopausal women
[65]. Obesity has been suggested as an independent factor
contributing to iron deﬁciency [60, 61, 63, 65], and studies
have correlated obesity, BMI, and increased hepcidin in
premenopausal women [66] and children [67]. Chronic
inﬂammation is associated with central obesity and has been
implicated in many obesity-related problems such as insulin
resistance[68,69].Obesemice(ob/obline)havesigniﬁcantly
higher plasma IL-6 levels than their lean counterparts, and
this diﬀerence is attributed to increased IL-6 expression in
adipose tissue, suggesting that adipose tissue contributes to
plasma inﬂammatory cytokine levels [70].
Adipose hypoxia is a contributing factor to increased
inﬂammation associated with obesity. Ye et al. [71]d e m o n -
stratedthatadiposetissueinob/obmiceisconsiderablymore
hypoxic than adipose tissue from lean mice. Diﬀerences in
O2 tension in ob/ob mice increased the expression of the
inﬂammatory cytokines TNF-α, IL-1, and IL-6. Increased
expression of cytokines was also demonstrated in 3T3-L1
cells cultured under hypoxic conditions (1% O2), suggesting
that the phenomenon of obesity-induced inﬂammation may
result from increased secretion of inﬂammatory cytokines
from hypoxic adipocytes found in deep fat pockets. Another
consequence of increased adiposity and adipocyte hypoxia
is macrophage inﬁltration of adipose tissue. Low partial
pressure of O2 in human adipose tissue is correlated
to macrophage inﬁltration [72, 73]. Several studies have
demonstrated that obesity in humans increases markers of
adipose macrophage content and subsequent inﬂammation
[73, 74].
Hepcidin expression is well known to be induced by
inﬂammation. IL-6 mediates hepcidin induction by increas-
ing the binding of the transcription factor STAT3 to hepcidin
promoter [20–22]. Considering that central obesity and
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Figure 2: Pathways for hypoxia-mediated hepcidin regulation.
Hypoxia or hypoxia mimetics result in HIF-1α accumulation.
HIF-1α has been proposed to be a direct, negative regulator of
hepcidin by binding to putative HIF response elements (HRE)
in the hepcidin promoter [38]. Expression of the hemojuvelin
cleaving enzymes TMPRSS6 and furin is increased by hypoxia
via HIF-1α [53, 55]. Hemojuvelin cleavage results in decreased
hepcidin promoter activation through inhibition of BMP/bone
morphogenetic response element (BRE) signaling [44]. Localized,
adipocyte hypoxia caused by central obesity results in elevated IL-
6 levels which can increase hepatocyte hepcidin expression via the
STAT3 binding site [75].
resulting adipocyte hypoxia increase systemic IL-6 [71], it
stands to reason that adipocyte hypoxia may be involved in
the hypoferremia of obesity through increased inﬂammatory
signaling of hepcidin. Hintze et al. [75] recently demon-
strated that Huh7 hepatocytes treated with conditioned
media from 3T3-L1 adipocytes cultured at 1% O2 had
signiﬁcantly greater hepcidin promoter activity and mRNA
levels compared to Huh7 cells treated with conditioned
media from 3T3-L1 cultured at 21% O2. Hypoxic adipocytes
had increased levels of both IL-6 and leptin mRNA. Leptin
and IL-6 have been demonstrated to induce hepcidin expres-
sion via the STAT3 pathway [75, 76] suggesting a possible
mechanism whereby adipocyte hypoxia may signal hepcidin.
When the hepcidin STAT3 binding site was mutated in the
hepcidin promoter, activity was diminished, suggesting that
adipocytehypoxiamayincreasehepcidinexpressionthrough
increased inﬂammation.
6. Summary
The recent discovery of hepcidin, which has been described
as a central regulator of iron homeostasis, has provided evi-
dence that iron balance is a tightly regulated process aﬀected
by a series of factors other than diet, to include hypoxia.
Hypoxia has profound eﬀects on iron absorption [30–
32] and results in increased erythropoiesis when humans
move from sea level to altitude [33]. Several mechanisms
or combinations thereof may explain decreased hepcidin
expressionmediatedbyhypoxia(Figure 2).ThereisevidenceAdvances in Hematology 5
that the hepcidin promoter may be a target for direct
negative regulation by the HIF/HRE system [38], although
not all studies support this assertion [42]. Despite some-
times conﬂicting results, studies utilizing hypoxia mimetics
that stabilize HIF proteins have consistently demonstrated
decreased hepcidin expression [38, 40, 42, 55] suggesting
that the HIF system is involved in hepcidin regulation
either directly or through upstream mediators. Localized
adipose hypoxia due to obesity may in part play a role in
hepcidin signaling and organismal iron metabolism. The
emerging literature concerning obesity, adipocyte hypoxia,
and inﬂammation suggests that the etiology of obesity-
related hypoferremia may be mediated in part through
increased hepcidin expression through inﬂammatory path-
ways originating from adipose tissue. Research in the area
of hypoxia and iron metabolism continues to provide novel
evidence of the molecular regulation of hepcidin and its
eﬀectsonironstatus.Itislikelythatrecentﬁndingswillresult
in the development of novel interventions aﬀecting hepcidin
expression, and, subsequently, iron balance.
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